Annemarie Moseley, COO/EVP Clinical Development at BELLICUM PHARMACEUTICALS, INC (BLCM), sold 25,000 shares at $18.04 ($438K) on 2016-12-01, disclosed to the SEC on 2016-12-05.
Open-market sale of $438k BLCM by COO/EVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.17 | 14,458 | $248K | 56.6% |
| 2 | $18.04 | 10,542 | $190K | 43.4% |
| Total | $17.54 avg | 25,000 | $438K | 100% |
| Filing → |
| BLCM | SELL | 2016-06-06 | $325K | — | Filing → |
| BLCM | SELL | 2016-01-06 | $713K | — | Filing → |
| BLCM | SELL | 2016-01-06 | $622K | — | Filing → |